To overcome the problems of Gd‐based contrast agents (GBCAs) and stimulator of interferon genes (STING) agonists, in this study, a Turbo‐charging system‐like GBCA termed as Turbo S are designed and constructed for MRI‐guided STING pathway‐activated cancer immunotherapy. Here, STING1 is linked to cancer.